Announcements Trials
Browse Landscape

Status

Available 1

Sponsor Class

INDUSTRY 1

Study Type

Observational 4Interventional 4Expanded_access 1

Sponsor

Cancer Type

CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 7Sarcoma 3Pancreatic Neoplasms 3Osteosarcoma 3Non-Muscle Invasive Bladder Neoplasms 3Breast Neoplasms 3Prostatic Neoplasms 2Ovarian Neoplasms 2Neoplasms 2Melanoma 2Urologic Neoplasms 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Small Cell Lung Carcinoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neurofibrosarcoma 1Neurofibromatoses 1Neurofibroma, Plexiform 1Neuroblastoma 1Myelodysplastic Syndromes 1Meningioma 1Mastocytosis, Systemic 1Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma 1Lung Neoplasms 1Leukemia, Myeloid, Acute 1Leukemia, Mast-Cell 1Leukemia 1Insulinoma 1

Interventions

mirdametinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Expanded_access × Neurofibromatoses × 90 days × Clear all
NCT05028166 2026-05-08

Individual Patient Compassionate Use of Mirdametinib

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

Available
CNS

Neurofibromatoses, Neurofibroma, Plexiform

Data powered by HemOnc (CC BY 4.0) Colophon âš¡